Protocatechuic Acid Attenuates Trabecular Bone Loss in Ovariectomized Mice

Area of Science:

• Biochemistry
• Pharmacology
• Osteoporosis Research

Background:

• Primary osteoporosis is linked to bone resorption from estrogen deficiency postmenopause.
• Protocatechuic acid (PCA), a plant-derived compound, has known biological activities but its antiosteoporotic effects are unestablished.
• Estrogen deficiency leads to increased osteoclast activity and bone loss.

Purpose of the Study:

• To investigate the antiosteoporotic activity of Protocatechuic acid (PCA) in a mouse model of postmenopausal osteoporosis.
• To evaluate the effects of PCA on bone resorption markers and osteoclast differentiation pathways.
• To assess PCA's impact on bone biomechanical properties and trabecular bone structure.

Main Methods:

• Ovariectomized (OVX) female ICR mice were supplemented with PCA (20 mg/kg/day) for 12 weeks.
• Serum levels of bone resorption markers (RANKL, osteocalcin, bone alkaline phosphatase, osteoprotegerin) were measured.
• mRNA expression of key osteoclast differentiation factors (cathepsin K, calcitonin receptor, NFATc1, TRAF6) in bone marrow cells was analyzed via RT-PCR.
• Bone biomechanical properties and trabecular bone structure were evaluated using microcomputed tomography.

Main Results:

• PCA supplementation significantly decreased serum RANKL, osteocalcin, and bone alkaline phosphatase, while increasing osteoprotegerin.
• PCA treatment attenuated the decrease in mRNA expression of cathepsin K, calcitonin receptor, NFATc1, and TRAF6 in bone marrow cells.
• PCA significantly improved trabecular bone loss and enhanced bone biomechanical properties in OVX mice.

Conclusions:

• Protocatechuic acid (PCA) effectively suppressed trabecular bone loss and improved bone quality in an ovariectomized mouse model.
• PCA demonstrated antiosteoporotic activity by modulating osteoclast differentiation and activity.
• PCA shows promise as a potential alternative therapeutic agent for preventing postmenopausal osteoporosis progression.